Pharma Journalist

Vendor Management & Outsourcing for Clinical Trials Summit
2025-06-10 - 2025-06-12 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
Vendor management processes are crucial for ensuring compliance, quality, and timely delivery at every stage, serving as the backbone of successful clinical trials. Acknowledging the transformative impact, the industry is prioritizing the optimization of these intricate processes, making significant investments to enhance key functions, improve performance, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges, until now…
Introducing the Vendor Management & Outsourcing for Clinical Trials Summit, built with the industry to the needs of vendor management, outsourcing and clinical operations professionals.
To know more visit: https://ter.li/d1jemt

4th World ADC Asia Summit
2025-06-10 - 2025-06-12 | Grand Hyatt Incheon, 208 Yeongjonghaeannam-ro 321beon-gil, Jung-gu, Incheon, South Korea
Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ
In 2025, Asia will continue leading ADC innovation, with growth in dual-payload ADCs, bispecific ADCs, and novel linker-payload technologies. Staying informed through clinical updates, connecting with new companies, and building collaborations will be key to seizing emerging opportunities.
The 4th World ADC Asia Summit (June 10-12, 2025, | Incheon, South Korea), part of the globally recognized World ADC series, serves as the premier platform for showcasing the latest advancements in R&D, clinical validation, and commercialization.
This industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region.
What’s New in 2025?
Three dynamic tracks covering discovery, preclinical, clinical, and CMC
Exclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert, the program offers something for professionals at every level
Unparalleled networking with leading experts and organizations
A Global Speaker Lineup
With 20+ new companies joining our esteemed panel from China, Japan, Korea, Taiwan, Singapore, the US, and Europe—featuring industry leaders such as AstraZeneca, AbbVie, HoneyBear Biosciences, Chiome Bioscience, and more—this is a must-attend event for anyone in the ADC field.
Learn more here: https://ter.li/iimxna

10th Annual Microbiome Movement Summit
2025-06-23 - 2025-06-25 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Returning for its 10th anniversary, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers, uniting experts across discovery, preclinical, translational, regulatory, and commercial sectors to drive innovation in the microbiome space.
Connect with over 140+ experts from diverse fields within microbiome R&D, including representatives from Pulmobiotics, Seres Therapeutics, BiomeBank, and PharmaBiome. Engage in dynamic discussions, forge valuable partnerships, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry.
What’s New for 2025?
– Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals, Siolta Therapeutics, MaaT Pharma, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics.
– 18 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra, Kanvas Bio, Alveolus Bio, Microviable Therapeutics, Unilever, Mikrobiomik, Jona, Nestle Health Science, and more, with each presenting their innovative approaches and breakthroughs in microbiome research.
– Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations, AI-driven strain engineering, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies.
– Advance Clinical Translation & Regulatory Success: Learn how companies are overcoming challenges in CMC, large-scale manufacturing, and regulatory approval, with insights on recent FDA approvals, IND-enabling studies, and global market access strategies.
Get your copy of the latest brochure here: https://ter.li/cdfr4c

CPHI & PMEC China 2025
2025-06-24 - 2025-06-26 | Shanghai New International Expo Centre, Shanghai, China
CPHI & PMEC China is Asia’s premier pharmaceutical event for sourcing, networking, learning and innovation with over 20 years’ experience of bringing together Chinese and global pharma professionals.

CPHI & PMEC China 2025 will cover more than 230,000 square meters of exhibition area, attract over 90,000 global attendees and 3,500 exhibitors, and hold more than 100 conferences during the exhibition.
CPHI & PMEC China 2025 showcases a wide range of pharmaceutical products and services, including: active pharmaceutical ingredients, Intermediates & fine chemicals, excipients, finished dosage formulation, biopharmaceuticals, natural extracts, CMO & CRO, machinery & equipment, packaging & drug delivery, laboratory equipment, cleanroom & pollution control etc.
Click here to register now.

5th Medical Device Software Development Summit
2025-06-24 - 2025-06-26 | The Royal Sonesta Boston, 40 Edwin H Land Blvd, Cambridge, MA, 02142, United States
The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies, real-world case studies, and expert insights to confidently develop, secure, and regulate cutting-edge medical device software – without compromise.
Dedicated to navigating the complexities of US and global regulations, addressing cybersecurity vulnerabilities, and managing legacy device updates, this summit unites 120+ industry leaders – from medical device giants to innovative start-ups – to explore actionable strategies, share best practices, and collaborate on solutions for ensuring the continuous compliance and security of cutting-edge software in a rapidly evolving market.
What Will you Gain:

Stay Ahead of Regulatory Changes: Gain insights from Biogen, Werfen, and Olympus on the latest FDA, EU MDR, and global compliance updates, ensuring your products meet evolving standards.
Secure & Accelerate Your Software: Learn how Medtronic, RETINA-AI, and Abbott are addressing cybersecurity risks, enhancing software validation, and leveraging AI-powered innovation to streamline development processes.
Unlock AI for Safer, Faster Development: Discover how HeartSciences, Kheiron, and Globe Biomedical are utilizing AI to expedite software testing, improve validation, and bolster cybersecurity, leading to safer and more efficient medical device development.

Don’t miss this summit – join us in Boston this June to stay ahead, gain crucial insights, benchmark and fuse knowledge from software, QA, RA and product teams to align innovation in software with evolving processes, cybersecurity, and global regulatory frameworks in new and legacy devices.
View the full Event Guide here: https://ter.li/cziksw

8th International Neoantigen Summit
2025-06-24 - 2025-06-26 | Steigenberger Airport Hotel Amsterdam, Stationsplein Zuid-West 951, 1117 CE Schiphol, Netherlands, 1117 CE, Netherlands
2024 saw a wealth of clinical progression with Nouscom, CureVac, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.
Ready to unite the global neoantigen community, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.
Join neoantigen leaders from the likes of AstraZeneca, Geneos Therapeutics, Evaxion Biotech and many more at this end-to-end meeting, focusing on the development of durable, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe, efficacious personalized or off-the-shelf therapeutic options to patients, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.
To know more visit: https://ter.li/zdfjes

5th Annual Induced Proximity-Based Drug Discovery Summit
2025-06-25 - 2025-06-26 | The Westin San Diego Bayview, 400 W Broadway, San Diego, CA, 92101, United States
Coming to San Diego, CA for the first time, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable.
Enabling leaders in biopharma and academia to identify novel MoAs, leverage advanced technologies to find targets more efficiently, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs, RIPTACs, tPRIMEs, RiboTACs and more, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective, potent small molecules of tomorrow.
Join 70+ experts in drug discovery, medicinal chemistry, chemical biology and structural biology from leading companies such as Genentech, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system
Download the event guide for full details: https://ter.li/blor1c

4th Liquid Biopsy for Precision Oncology East Coast
2025-06-26 - 2025-06-27 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, and a renewed mission: to accelerate access to more sensitive, less invasive testing by addressing the most pressing challenges across the entire patient care continuum.
This year, we’ve updated the Summit’s name and expanded its scope. What began with a focus on early detection and recurrence monitoring has grown to reflect the full breadth of innovation across the liquid biopsy space – from MRD and treatment response to emerging applications in rare diseases, novel analytes, and beyond.
Bringing together leaders in Biomarker Development, Translational Research, Diagnostics, Clinical Development, Pathology, and beyond, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies.
Take home actionable insights to ensure you’re maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology and be part of the conversations that will drive meaningful change for patients worldwide.
What’s more, this event is completely *FREE for drug developers and researchers for the entire 2 day conference, so claim your pass here (it only takes 2 minutes): https://ter.li/mr0yvh
If you need to explore the full event guide in more detail, feel free to download the brochure here: https://ter.li/mxugsc
T&Cs are available on the website.

ESG in Life Sciences Summit West
2025-07-08 - 2025-07-10 | The Clift Royal Sonesta San Francisco, 495 Geary St, San Francisco, CA, 94102, United States
The ESG in Life Sciences Summit West – Mastering ESG Compliance & Strategic Sustainability in Life Sciences in 2025.
As ESG becomes a key differentiator for securing business and investment, life sciences companies are ramping up sustainability efforts – expanding teams, funding new initiatives, and integrating ESG into corporate strategy. Yet, with shifting global reporting requirements, the new administration’s stance on sustainability, and the impact of CSRD on U.S. operations, many companies are struggling to find the golden ticket on how they can future-proof ESG initiatives and ensure accuracy in reporting?
At the same time, mounting pressure from investors, consumers, and employees to accelerate environmental and social initiatives is leaving many searching for the most effective strategies to navigate the evolving ESG landscape.
Following the success of our Boston and European editions, the ESG in Life Sciences Summit West is bringing together senior leaders in ESG, Sustainability, Compliance, Procurement, Supply Chain, and Finance from across the West Coast to:

Decode the impact of evolving U.S. and EU regulations on ESG reporting
Drive sustainable supply chain transformation
Optimize ESG strategies for business growth

Join us in driving the future of Life Sciences sustainability – turning ambition into action, compliance into opportunity, and responsibility into lasting impact for people and the planet! Find out more here: https://ter.li/oggmq8

3rd ADC Toxicity Summit
2025-07-08 - 2025-07-10 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities, the industry must address key hurdles in preclinical models, patient selection, ADC design, and cross-disciplinary communication to accelerate the next wave of safer, more effective ADCs.
The 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.
To know more visit: https://ter.li/57358v

3rd Obesity & Weight Loss Summit
2025-07-14 - 2025-07-16 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The 3rd Obesity & Weight Loss Summit has been announced and is set to ignite the field. The summit will unite experts to harness novel targets and GLP combination therapies to improve efficacy, tolerability, and longer lasting clinical outcomes.

Join us at this unique, industry-led summit to:

Discover groundbreaking combination therapies and novel targets to minimize and manage side effects to improve patient tolerability with Boehringer Ingelheim and Altimmune
Explore innovative approaches for preserving muscle mass whilst still achieving significant weight loss to prevent sarcopenia with Regeneron and iBio
Investigate cutting-edge advancements in drug delivery technologies, including long-acting formulations and novel administration routes for simpler patient use with Biolexis and Syntis Bio
Learn strategies to drive long-term weight management success by personalizing treatment for more prolonged patient continuation and satisfaction with Prive Bio and Fractyl Therapeutic

Hear from the titans of the pharmaceutical industry – Eli Lilly, Novo Nordisk, AstraZeneca, Altimmune, High Tide Therapeutics, RenBio, and many more – as they share their groundbreaking research and strategies for developing more effective, tolerable, and long-lasting weight management solutions.
Obesity rates are increasing, and the pressure is on for real change. Don’t miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations, and be part of the solution. The future of weight loss treatment is being written now – be there!
For more information, view the full Event Guide here: https://ter.li/rish42

5th Inner Ear Disorders Therapeutics Summit
2025-07-15 - 2025-07-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
Building on recent breakthroughs in gene therapy, 2025 is poised for major advancements in cell transplants, gamma secretase inhibitors, anti-inflammatory programs, and more to address the growing unmet need for more transformative hearing loss treatments.

With an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions, there has never been a more critical time for the field to unite and drive progress.
Coined by industry as the only meeting of its kind, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clinical bottlenecks, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape.
With pioneering insights from Regeneron, Biogen, Acousia, Rinri, Ting Therapeutics, Lineage Cell Therapeutics, Gateway and more, join 50+ of your peers to:

Advance translatable models to recapitulate complex human inner ear pathophysiology
Deepen knowledge of molecular and genetic pathways underlying age-related, noise-induced, and congenital hearing loss to uncover druggable pathways
Evaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations
Overcome translational challenges of bringing advanced therapies, including small molecule and cell-based approaches, to the clinic
Uncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants
Hear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space

Join this unparalleled forum of biotech innovators, pharma stakeholders, medical device manufacturers, and leading academics in a collaborative atmosphere to advance otoprotection, hearing restoration, and gene therapy R&D and transform the treatment of hearing loss.
Find out more in our brochure: https://ter.li/22rawz

5th mRNA-Based Therapeutics Summit
2025-07-21 - 2025-07-23 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The mRNA field is on the cusp of revolutionary change, with cancer vaccines, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval.
To shine light on emerging areas and the latest progress, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world’s largest, end-to-end mRNA conference, gathering 350+ global stakeholders, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA, Circular RNA & SaRNA fields including Moderna, Pfizer, BioNTech, Grann Pharmaceuticals, Celestial Therapeutics.
Discover the realms of new infectious disease platforms, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery, Pre-Clinical Development, Clinical Development and Manufacturing & CMC, as your one-stop-shop scientific content and partnering forum to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need.
Download the event guide for full details: https://ter.li/esarrv

13th Tumor Models Summit Boston
2025-07-22 - 2025-07-23 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
This July, the 13th Tumor Models Summit Boston returns, uniting 180+ preclinical and translational experts from biopharma and solution providers.
This year’s dual-track program will empower you and your team to implement reproducible, predictive oncology models, and bridge the translational gap in a time- and cost-effective manner.
Expect to gain exclusive insights into:

The latest applications of tumoroids, patient-derived in vivo, ex vivo, in silico and genetically engineered models
Optimized protocols to humanize complex in vitro and mouse models
Applying reverse translation and clinical learnings to better stratify patients, focus treatment regimens, and improve patient outcomes
Practical applications of digital pathology and spatial biology to advance your model selection strategy

Event information and quick links:

Location: Westin Boston Seaport District, Boston, MA
Dates: July 22-23, 2025
Event Guide: https://ter.li/dz9th5
Registration (FREE* for biopharma!): https://ter.li/d6bden

*Subject to terms and conditions, visit the website to learn more: https://ter.li/d6bden

4th Targeted Radiopharmaceuticals Summit US
2025-07-29 - 2025-07-31 | The Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, CA, 92122, United States
As demand for radiopharmaceuticals rises, the industry is focused on strengthening isotope supply, improving patient access, and accelerating therapeutic development.

Join us at the 4th Targeted Radiopharmaceuticals Summit US in San Diego this July for the premier platform dedicated to radiopharmaceutical therapeutics and theranostics, featuring:

50+ Expert Speakers from leading biotech, pharma, and research institutions, including Ratio Tx, Abdera, Alpha-9
Oncology, Novartis, AstraZeneca, UCLA, UCSF, and more
275+ Industry Attendees driving advancements from bench to bedside
11+ Hours of Networking with top professionals
3 Dedicated Tracks: Discovery & Preclinical, Translational & Clinical, and Clinical & Supply Chain, curated to address key challenges

Offering a tightly focused agenda dedicated to industry-specific topics, this event is designed to advance approvals and commercialization.
Explore critical areas such as isotope supply, clinical development, regulatory clarity, novel molecule design, investment and funding and much more.
Don’t miss this essential event for anyone involved in the radiopharmaceuticals space!
View the exclusive program here.

Operationalize: Expanded Access Programs Summit West
2025-07-29 - 2025-07-31 | The Clift Royal Sonesta, 495 Geary Street, San Francisco, CA, 94102, United States
The Operationalize: Expanded Access Programs Summit West is coming to San Francisco! (July 29-31).
Following the successful Boston and London meetings, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need.
This Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies!
Find out more at our website: https://ter.li/9ft05e.
Join 60+ experts, from Eli Lilly, Gilead, Ultragenyx, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.

5th Fc-Mediated Function Summit
2025-07-29 - 2025-07-31 | Hilton Boston Back Bay, 40 Dalton St, Boston, MA, 02115, United States
The landscape of Fc-mediated therapies is undergoing a radical transformation, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification.
This year, we’re evaluating the cutting-edge of Fc biology and engineering, diving deep into the game-changing potential of novel Fc modifications, bispecific formats, and targeted effector functions to revolutionize the treatment of cancer, autoimmune diseases, and beyond. Hear from the titans of the pharmaceutical industry, including AbbVie, Novartis, and UCB as well as innovative biotechs including Seismic Therapeutics, Paradigm Immunotherapies, and many more – as they share their groundbreaking research and strategies for developing more effective, safer, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky, and the pressure is on to continue this success and develop best-in-class treatments.
Why Attend?

Navigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles
Confront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications
Hear from 22+ industry luminaries and thought leaders, including Sally Ward and Richard Blumberg, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics, including Argenx, UCB, and Boehringer Ingelheim

Don’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function, forge crucial collaborations, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it!
Register now.

5th Next Generation Gene Therapy Vectors Summit
2025-07-29 - 2025-07-31 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The 5th Next Generation Gene Therapy Vectors Summit

Recent announcements from major pharmaceutical companies scaling back their AAV gene therapy pipelines have raised concerns across the field. However, this is not the end. It is an opportunity to reset, refocus, and rise to the challenge. While issues such as liver toxicity, pre-existing antibodies, and high manufacturing costs remain significant, so too does the unmatched potential of AAV vectors. From their ability to cross the blood-brain barrier to delivering single-stranded DNA for single-dose cures, AAV continues to offer enormous therapeutic promise.
The 5th Next Generation Gene Therapy Vectors Summit returns to Boston this September to spotlight the scientists and leaders who are continuing to innovate in vector design. This meeting is designed for those who understand that strategic setbacks can often pave the way for transformative breakthroughs, as we saw in the early development of ADCs.
Over the course of 3 days, the summit will bring together experts in vector engineering, translational science, and clinical development to explore how the field can advance in a more refined and resilient direction. Attendees will hear from thought leaders such as Daniel Cohen (Spark Therapeutics), Eric Kelsic (Dyno Therapeutics), Jorge Santiago-Ortiz (Apertura Gene Therapy), Lolita Petit (Coave Therapeutics), Ralf Schmid (Novartis), and Roxanne Croze (4D Molecular Therapeutics).
The program will explore the latest innovations in capsid engineering, novel strategies to overcome immune responses, scalable systemic delivery technologies, and key clinical insights that can shape future development pipelines.
Whether your focus is vector optimization, CMC, or clinical translation, this summit provides a valuable opportunity to connect with the experts and technologies leading the next phase of gene therapy innovation. Join the community in Boston this July and help shape a safer, smarter, and more successful future for AAV.
Find Out More Here: https://ter.li/8qkdsh

LEAP HR: Life Sciences East
2025-08-05 - 2025-08-07 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
Join us this August in Boston, MA for the 9th LEAP HR: Life Sciences East.
Connect with 200+ leadership professionals in biopharma dedicated to attracting, retaining and developing critical talent to deliver their organizations mission. Engage with HR leaders who are also navigating a period of uncertainty amongst: regulation changes, financial uncertainties, supply chain disruptions, and changing workforce dynamics. Leave with a ready-made support network of industry peers committed to building high-performing organizations.
Explore 40+ case studies from leading drug development organizations on shifting to new systems of empowered teams, accelerating the development of both current and future leaders, and optimizing global team dynamics across diverse business layers.
Find out more now: https://ter.li/v3bct4

3rd ADC Linker & Conjugation Summit
2025-08-19 - 2025-08-21 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
As dual-payload and novel MoA payload ADCs continue to reshape the therapeutic landscape, the 3rd ADC Linker & Conjugation Summit returns as the definitive forum for ADC chemists and bioconjugation specialists aiming to overcome persistent challenges in hydrophobicity, aggregation, and linker stability.
This three-day technical deep dive is your chance to:

Discover next-generation conjugation strategies and site-specific technologies
Tackle the unique challenges of dual-payload and novel payload ADCs
Benchmark cutting-edge solutions for improved DAR control and linker stability
Advance ADC reproducibility and performance with chemistries beyond maleimide

Join 80+ industry experts, including ADC chemists, biotech innovators, and service providers, all focused on refining ADC design for enhanced PK profiles and safety.
Explore the brand-new event guide and be part of the community driving the next wave of ADC innovation. https://ter.li/387nz1

9th IPF Summit
2025-08-19 - 2025-08-21 | Hilton Boston Park Plaza, 50 Park Plaza, Boston, MA, 02116, United States
This August, the 9th IPF Summit returns as the industry’s must attend summit, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks, to shape the future of pulmonary fibrosis drug development.
Be one of the first to view the agenda here: https://ter.li/moky9n
A Snapshot of What Awaits You in 2025:

Case Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success
Brand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos
Navigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves, with input from Boehringer Ingelheim, BMS, and Insilico Medicine
Enhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025, featuring case studies from GSK, Boehringer Ingelheim, and others.

If ever there was a time to invest in this community and a conference, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster.
Find all the information needed here: https://ter.li/moky9n

5th Oligonucleotides for CNS Summit
2025-08-27 - 2025-08-29 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
In a year where neurology has overtaken cancer as the number one indication prioritized by oligonucleotide drug developers, now is the time to stay at forefront of ASO and siRNA innovation. Returning to Boston, this August, the 5th Oligonucleotides for CNS Summit unites 100+ biopharma leaders across RNA biology, oligonucleotide chemistry, DMPK, pharmacology, and platform technology, to discover the latest advancements in brain delivery, chemistry, nonclinical safety and more!
Join your peers Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to overcome key challenges, build cross-modality relations, unpack the latest clinical data and redefine the landscape of oligonucleotide research.
What to Expect:

Benchmark your chemistry and biology innovations with dual-tracked workshops developed for medicinal chemists and neurobiologists
Hear from 10+ new speakers, including insights from the FDA and companies breaking ground across neuromuscular, neurodegenerative, neurodevelopmental and ultra-rare indications
Explore the next wave of delivery tech, from TfR1 and AOCs to computational CNS PK/PD modeling and novel RNA editing approaches

Capitalize on the recent ‘oligonucleotide boom,’ by attending this meeting!
To know more visit: https://ter.li/uw2usc

Wearable Injectors and Connected Devices USA
2025-09-08 - 2025-09-09 | COURTYARD BY MARRIOTT BOSTON DOWNTOWN, 275 Tremont St, Boston, MA, 02116, United States
Engage in the Latest Innovations in Wearable Injectors and Connected Devices! SAE Media Group’s 3rd Annual Wearable Injectors and Connected Devices USA Conference returns to Boston on September 8–9, 2025, bringing together the latest innovations in connected, on-body drug delivery. Designed for professionals in injectable drug delivery and digital health, this two-day event will explore critical advancements in large-volume drug delivery, digital integration, and user-centric design. Through real-world case studies and expert-led sessions, you’ll gain actionable insights into the technologies and strategies shaping the future of combination products. Take part in a unique platform to connect and network with key players across pharma and device development, from R&D and engineering to human factors and regulatory affairs. Whether you’re optimizing your current portfolio or exploring new drug-device opportunities, this is your chance to stay ahead in a rapidly evolving field and be part of the conversation to shape its future.
To know more click here

4th PAT & Real Time Quality Summit
2025-09-09 - 2025-09-11 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 4th PAT & Real Time Quality Summit is the leading industry-specific forum for Process Analytical Technology (PAT) professionals in the biotech and pharmaceutical sectors. Taking place at a pivotal time, with the recent release of USP General Chapter <1037> and anticipated FDA guidelines on PAT due in July 2025, this summit is tailored to help organizations stay ahead of regulatory shifts and technological advancements.
Bringing together over 80+ PAT experts from leading pharmaceutical companies, biotechs, and CDMOs, the summit will address critical challenges such as high investment costs, integration with legacy systems, and data management. Through real-world case studies, panel discussions, and strategic roadmaps, you will explore how PAT is rapidly advancing in areas like biopharmaceuticals, personalized medicine, and complex therapies.
Join your peers this September to:

Benchmarking strategies with top industry leaders and exploring cutting-edge technologies.
Overcoming tech transfer challenges for small molecules and complex therapies.
Understanding new FDA guidelines and aligning with GMP compliance.
Demonstrating ROI and gaining executive buy-in through improved efficiency and reduced batch failures.
Real-Time Release Testing, enabling faster timelines while maintaining high quality standards.

You are guaranteed to leave with actionable insights into PAT integration across the drug development lifecycle—from regulatory updates to real-time release strategies—ensuring smoother approvals, improved manufacturing processes, and enhanced product consistency.
With speakers from renowned organizations such as AstraZeneca, GlaxoSmithKline, and Pfizer, this summit provides an invaluable platform to exchange ideas, form collaborations, and successfully navigate the future of PAT in pharma and biopharma.
Don’t miss this opportunity to connect with the brightest minds in PAT and help shape the next generation of pharma manufacturing.

2nd ADC & Novel Conjugates Partnering & Investment Summit
2025-09-09 - 2025-09-10 | Hyatt Regency Boston, One Ave. de Lafayette, Boston, MA, 02111, United States
Refine your strategy, sharpen your positioning, and meet the right partners – all at the most efficient networking event of the ADC conference calendar.
Back for its second year, the ADC Partnering & Investment Summit unites 100+ top ADC companies, pharma leaders, and investors for hyper-aligned and more efficient business networking.
Unite with other ADC business development leaders where cutting-edge science meets strategic networking:

Connect directly with decision-makers in a less competitive setting

Understand how others are positioning themselves to refine your own differentiation

Gain insights from scientific pioneers shaping the future of ADCs to define your strategic direction

VIEW THE FULL EVENT GUIDE
Secure your place here or get in touch with the team – info@hansonwade.com

15th World Clinical Biomarkers & Companion Diagnostics Summit
2025-09-22 - 2025-09-25 | Westin Boston Seaport District, 425 Summer St, Boston, MA, 02210, United States
Fuelled by industry excitement like the world-first approval of a digital pathology CDx, the biomarker and diagnostics field continues to surge.
Uniting 600+ precision medicine experts this September, the 15th World Clinical Biomarkers & Companion Diagnostics Summit returns with a refreshed 4-day, 3-track, 50+-speaker program, ready to facilitate connection-making and knowledge-sharing to bring affordable precision healthcare to patients with unmet need.

600+ attendees from biopharma and diagnostic providers
50+ precision medicine experts on the speaker faculty
66+ data-driven presentations spanning the end-to-end of drug-diagnostic co-development

Event guide: https://ter.li/dr5749
Register (FREE* tickets available for biopharma!): https://ter.li/4zaizd

7th Exosome-Based Therapeutic Development Summit
2025-09-23 - 2025-09-25 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Showcasing biopharma innovation in 2025, the 7th Exosome-Based Therapeutics Development Summit returns to Boston as the industry’s only dedicated forum covering the full exosome development pipeline, from discovery and optimized characterization to scalable manufacturing and clinical translation.

This year’s Summit brings together key players from Direct Biologics, Rion, Aegle Therapeutics, Aruna Bio, EXO Biologics, and more, as the field accelerates toward the first-ever exosome and EV approvals.
Across three content-packed days, you’ll gain actionable insights and strategic takeaways to support your journey from early-stage research to commercialization.
Join 80+ key exosome and extra-cellular vesicle experts specializing in Exosome Biology, R&D, CMC to Business Development for an unrivalled learning and networking opportunity to roadmap the therapeutic efficacy and delivery potential of exosomes and EVs towards commercialization and patients in need.
Don’t miss the chance to lead this field by driving breakthroughs in regenerative and precision medicine and position your pipeline for success in this rapidly advancing space.
Want to find out more? Download the Official 2025 Brochure here: https://ter.li/c1jk7p
To access tickets & discounts, follow this link: https://ter.li/pi0pdc

6th Genome Editing Therapeutics Summit
2025-09-29 - 2025-10-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
With baby KJ successfully receiving the world’s first personalized CRISPR therapy, alongside continued innovation across in vivo and base editing, and rapid ex vivo clinical progress, the genome editing field stands at a pivotal juncture.
To mark this definitive CRISPR milestone, the 6th Genome Editing Therapeutics Summit returns to Boston to celebrate ongoing progress, whilst also tackling end-to-end challenges from discovery through to commercial strategy.
Unite with the industry’s leading minds, as they advance delivery specificity, spearhead in vivo editing, ensure precise targeting, improve translatability, and build robust clinical strategies to unlock precise, durable and safe therapeutics.
The 2025 Expert Speaker Line-up Includes:

Kiran Musunru, Professor, Translational Research, University of Pennsylvania
TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics
Nageswara Kollu, Senior Director, Gene Therapy, Apellis Pharmaceuticals
Alexandria Petrusich, Vice President, Clinical Science, Prime Medicine
Bradley Ringeisen, Executive Director, Innovative Genomics Institute
Chris Brown, Vice President, Discovery, Metagenomi
Anjulika Chawla, Vice President, Medical Affairs, Clinical Lead, Bluebird Bio

Alongside 20+ data-driven presentations, this year’s program will feature a deep-dive workshop dedicated to the impact of baby KJ, led by Innovative Genomics Institute, HuidaGene Therapeutics and the University of Pennsylvania.
Ensure you are part of the most anticipated gene editing event of the year!
To know more visit: https://ter.li/rd7cax

LEAP TA: Life Sciences
2025-09-29 - 2025-10-01 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
As 2025 shapes up to be a transformative year for talent acquisition in life sciences, the 7th LEAP TA: Life Sciences returns to Boston, MA this September (29 – October 1), uniting over 120 senior TA professionals from industry pioneers including Pfizer, AbbVie, Bristol Myers Squibb, Bayer, Edwards Lifesciences, The Jackson Laboratory, and more.
This is the only event dedicated entirely to helping biopharma reimagine how they attract, engage, and retain top talent in an increasingly complex hiring landscape. In a time of political uncertainty, evolving regulations, and rapid scientific advancement, hiring in life sciences has never been more challenging, or vital to long-term success.
Over three high-impact days, uncover how TA leaders are:

Navigating visa challenges, DEI pushback, and new workforce expectations
Leveraging AI, redefined employer branding, and technology to build future-ready teams
Driving value-driven recruitment in the face of political and market disruption
Adapting to shifting skills requirements through innovative sourcing strategies

From small biotechs to global pharma giants, this event spotlights real-world case studies and actionable insights from across the industry, all designed to equip you with the tools to compete for niche, scientific, and technical talent in today’s market.
Whether you’re looking to streamline time-to-fill, reduce turnover, or build a more resilient and diverse talent pipeline, LEAP TA: Life Sciences offers a unique opportunity to step back from day-to-day execution, connect with your peers, and rethink what’s possible in TA.
Join the most forward-thinking talent acquisition leaders in life sciences to shape the future of hiring in 2025 and beyond.

9th MASH Drug Development Summit
2025-09-29 - 2025-10-01 | Hyatt Regency Boston / Cambridge, 575 Memorial Dr, Cambridge, MA, 02139, United States
The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era, the race is on to deliver more effective, patient-centered treatments.
This year, dive into novel mechanisms of action, non-invasive biomarkers, and strategic combination and sequential therapies. Hear from experts at Eli Lilly, Pfizer, Takeda, Madrigal, Akero, 89 Bio, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations.
Join 60+ MASH scientists and drug developers, gain critical insights, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches.
Find out more now: https://ter.li/d9r0pm
